دورية أكاديمية
أعرض في EDS

Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apob tm2Sgy /Ldlr tm1Her/J mice.

التفاصيل البيبلوغرافية
العنوان: Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apob tm2Sgy /Ldlr tm1Her/J mice.
المؤلفون: Thota LN; Research Scholar, Manipal University, (Madhav Nagar, Manipal) at Molecular Immunology Unit Thrombosis Research Institute, Bangalore, India., Ponnusamy T; Research Scholar, Manipal University, (Madhav Nagar, Manipal) at Molecular Immunology Unit Thrombosis Research Institute, Bangalore, India., Philip S; Molecular Immunology unit, Thrombosis Research Institute, Bangalore, India., Lu X; Molecular Immunology unit, Thrombosis Research Institute, London, UK., Mundkur L; Molecular Immunology unit, Thrombosis Research Institute, Bangalore, India. lakshmi.mundkur@triindia.org.in.
المصدر: Scientific reports [Sci Rep] 2017 Jun 21; Vol. 7 (1), pp. 3997. Date of Electronic Publication: 2017 Jun 21.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Apolipoprotein B-100/*administration & dosage , Atherosclerosis/*drug therapy , Bacterial Outer Membrane Proteins/*administration & dosage , Chaperonin 60/*administration & dosage , Peptides/*administration & dosage, Animals ; Aorta/drug effects ; Aorta/physiopathology ; Apolipoprotein B-100/genetics ; Atherosclerosis/genetics ; Atherosclerosis/immunology ; Atherosclerosis/pathology ; Bacterial Outer Membrane Proteins/chemistry ; CTLA-4 Antigen/genetics ; Cell Proliferation/drug effects ; Chaperonin 60/genetics ; Chlamydophila pneumoniae/chemistry ; Diet, High-Fat/adverse effects ; Forkhead Transcription Factors/genetics ; Gene Expression Regulation/drug effects ; Humans ; Macrophages/drug effects ; Macrophages/immunology ; Matrix Metalloproteinase 9/genetics ; Mice ; Peptides/genetics ; Sinus of Valsalva/drug effects ; Sinus of Valsalva/immunology ; Spleen/drug effects ; Spleen/immunology ; T-Lymphocytes, Regulatory/drug effects ; Thromboplastin/genetics ; Transforming Growth Factor beta/genetics
مستخلص: Atherosclerosis is the leading cause for cardiovascular mortality. We determined the effect of multi-antigenic construct expressing three peptides AHC (ApoB100, HSP60 and outer membrane protein of chlamydia pneumonia) in stabilizing advanced atherosclerosis in Apob tm2Sgy /Ldlr tm1Her/J mice. Atherosclerosis was induced by feeding high fat diet (HFD) to mice for 10 weeks, followed by five oral dosing with purified AHC or ovalbumin on alternate days and continued on HFD for another 10 weeks. Tolerance was associated with significantly higher numbers of regulatory T cells both in aortic sinus and spleen with higher mRNA expression of CTLA4 (3 fold), Foxp3 (1.4 folds) and TGF-β (1.62) in aorta. Tregs cells were found to induce alternate activation of macrophages to M2 phenotype, with a reduction in plaque inflammation. AHC treatment showed evidence of plaque stabilization as observed by reduction in plaque necrosis in aortic sinus (35.8%) and in brachiocephalic artery (26%), with reduced expression of Tissue factor and MMP9. Macrophage apoptosis was reduced and collagen content was enhanced by treatment. Our results suggest that tolerance to atherogenic peptides increases regulatory T cells which activate M2 macrophages, prevent T cell proliferation and reduce plaque destabilization and inflammatory markers thus providing evidences for plaque stabilization in mice with advanced atherosclerosis.
التعليقات: Erratum in: Sci Rep. 2018 Oct 24;8(1):15974. (PMID: 30356091)
References: PLoS One. 2012;7(4):e35835. (PMID: 22558236)
BMC Med. 2014 Mar 18;12:47. (PMID: 24642015)
Atherosclerosis. 2012 Dec;225(2):461-8. (PMID: 23078881)
Ann Glob Health. 2014 Jan-Feb;80(1):13-23. (PMID: 24751561)
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):280-7. (PMID: 25414253)
F1000Prime Rep. 2014 Mar 03;6:13. (PMID: 24669294)
Arch Med Sci. 2016 Dec 1;12 (6):1308-1316. (PMID: 27904523)
Atherosclerosis. 2010 Mar;209(1):74-80. (PMID: 19765709)
J Lipid Res. 2010 May;51(5):1208-17. (PMID: 20007839)
Circulation. 2003 Sep 9;108(10):1232-7. (PMID: 12912803)
PLoS One. 2013;8(3):e58364. (PMID: 23505495)
Front Immunol. 2014 Oct 27;5:532. (PMID: 25386178)
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19446-51. (PMID: 18042719)
Autoimmun Rev. 2010 Oct;9(12):849-52. (PMID: 20692379)
J Clin Invest. 2013 Jan;123(1):179-88. (PMID: 23257360)
J Clin Invest. 2013 Mar;123(3):1323-34. (PMID: 23426179)
Annu Rev Immunol. 2009;27:165-97. (PMID: 19302038)
Atherosclerosis. 2010 Oct;212(2):472-80. (PMID: 20609438)
Nat Med. 2006 Feb;12(2):178-80. (PMID: 16462800)
Circulation. 2009 Nov 17;120(20):1996-2005. (PMID: 19884470)
FASEB J. 2001 Dec;15(14):2730-2. (PMID: 11687507)
Can J Cardiol. 2016 Aug;32(8):1008.e1-1008.e10. (PMID: 27062234)
J Am Coll Cardiol. 2007 Aug 7;50(6):547-50. (PMID: 17678739)
Nat Rev Immunol. 2013 Oct;13(10):709-21. (PMID: 23995626)
Atherosclerosis. 2009 Mar;203(1):59-66. (PMID: 18639878)
Cytokine Growth Factor Rev. 2015 Dec;26(6):673-85. (PMID: 26005197)
Nat Rev Cardiol. 2015 Jan;12(1):10-7. (PMID: 25367649)
Circ Res. 2000 Jan 7-21;86(1):101-8. (PMID: 10625311)
Circulation. 2006 Oct 31;114(18):1968-76. (PMID: 17060383)
PLoS One. 2016 Feb 17;11(2):e0148873. (PMID: 26886778)
Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2677-83. (PMID: 17901374)
FEBS Lett. 2003 Feb 11;536(1-3):6-11. (PMID: 12586329)
BMC Immunol. 2012 Jun 15;13:31. (PMID: 22703233)
Eur Heart J. 2008 Aug;29(16):2023. (PMID: 18337236)
Circulation. 2001 Nov 13;104(20):2447-52. (PMID: 11705823)
Curr Atheroscler Rep. 2013 Oct;15(10):359. (PMID: 23982263)
PLoS One. 2012;7(6):e39790. (PMID: 22761902)
Atherosclerosis. 2012 Nov;225(1):56-68. (PMID: 22959702)
Circulation. 2001 Jul 17;104(3):365-72. (PMID: 11457759)
Mediators Inflamm. 2015;2015:816460. (PMID: 26089604)
Clin Microbiol Rev. 2001 Apr;14(2):430-45. (PMID: 11292646)
Autoimmun Rev. 2010 Oct;9(12):830-4. (PMID: 20678595)
Cell. 2008 May 30;133(5):775-87. (PMID: 18510923)
J Immunol. 2008 May 1;180(9):5916-26. (PMID: 18424711)
Cardiovasc Res. 2004 Jun 1;62(3):603-9. (PMID: 15158153)
Cell Adh Migr. 2007 Oct-Dec;1(4):171-5. (PMID: 19262139)
Trends Immunol. 2004 Dec;25(12):677-86. (PMID: 15530839)
Cell. 2011 Apr 29;145(3):341-55. (PMID: 21529710)
Exp Clin Cardiol. 2002 Spring;7(1):40-53. (PMID: 19644578)
PLoS One. 2012;7(8):e42507. (PMID: 22880008)
Int J Cardiol. 2014 Aug 1;175(2):340-51. (PMID: 24962340)
J Am Coll Cardiol. 2013 Mar 12;61(10):1041-51. (PMID: 23473409)
Arterioscler Thromb Vasc Biol. 2010 May;30(5):946-52. (PMID: 20167655)
Circ Res. 2014 Jun 6;114(12):1852-66. (PMID: 24902970)
Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):12-22. (PMID: 14604830)
المشرفين على المادة: 0 (Apolipoprotein B-100)
0 (Bacterial Outer Membrane Proteins)
0 (CTLA-4 Antigen)
0 (Chaperonin 60)
0 (Ctla4 protein, mouse)
0 (Forkhead Transcription Factors)
0 (Foxp3 protein, mouse)
0 (Peptides)
0 (Transforming Growth Factor beta)
9035-58-9 (Thromboplastin)
EC 3.4.24.35 (Matrix Metalloproteinase 9)
EC 3.4.24.35 (Mmp9 protein, mouse)
تواريخ الأحداث: Date Created: 20170623 Date Completed: 20181226 Latest Revision: 20181226
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5479867
DOI: 10.1038/s41598-017-04183-w
PMID: 28638138
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-017-04183-w